Login / Signup

Enhancing diversity of clinical trial populations in multiple sclerosis.

Kathryn C FitzgeraldJeremy ChatawayBarbara E BiererMarcia L FinlaysonElena H Martinez-LapiscinaJennifer PanagouliasMaria Pia SormaniMitzi Joi WilliamsLilyana Amezcua
Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
These recommendations provide sponsors and investigators with methods of improving diversity and inclusivity of clinical trial populations in MS.
Keyphrases
  • clinical trial
  • multiple sclerosis
  • phase ii
  • open label
  • double blind
  • study protocol
  • mass spectrometry
  • white matter
  • phase iii
  • genetic diversity
  • ms ms
  • clinical practice
  • randomized controlled trial